title: The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation.
abstract: A clear protection of the gastrointestinal tract and an evident anti-inflammatory effect were shown for a novel stomach pentadecapeptide BPC 157 (i.p./i.g.) in comparison with several reference standards in various ulcer models along with a protection of endothelium and particular interaction with the NO-system. Thus, we evaluated whether this pentadecapeptide along with other gastroprotective agents could affect angiogenesis and the healing process in vivo using a procedure initially described by Szabo and co-workers. In each rat, two sterile sponges (1 x 1 x 0.25 cm; V = 0.25 mL) with the same quantities of BPC 157 (10 ng x mL(-1), 10 microg x mL(-1), 50 microg x kg(-1)) or reference agents (cimetidine: 10, 100, 500 mg x mL(-1); ranitidine: 2.5, 25, 250 mg x mL(-1); famotidine: 10, 50, 100 mg x mL(-1); omeprazole: 10, 50, 100 mg x mL(-1); sucralfate: 1, 5, 10 mg x mL(-1) were implanted subcutaneously in the lumbar region. The sponges were removed after 3 or 7 d, fixed in formalin, and processed for histologic and histochemical evaluation and morphometry assessment. Compared with the control values, the number of newly formed endothelial spaces inside newly formed granulation tissue was markedly increased in all animals treated with BPC 157, cimetidine, ranitidine, famotidine, sucralfate and omeprazole, a consistent finding noted after either 3 or 7 d. Compared with control values, markedly more granulation tissue was noted in the rats in the groups of animals treated with BPC 157 (50 microg) and in the rats treated with sucralfate in all dosages used, euthanized after 3 d. In all groups treated with H2-blockers however, similar values to those of controls were noted. Thus, it could be concluded that an evident angiogenic property was consistently noted for the novel pentadecapeptide BPC 157, H2-blockers (cimetidine, famotidine and ranitidine) and omeprazole, besides the well known angiogenic effect of sucralfate. Furthermore, unlike H2-blockers and omeprazole, BPC 157 stimulates the formation of granulation tissue, suggesting a particular activity, similar to that previously noted for sucralfate.
authors.affiliation: Medical and Veterinary Faculty, University of Zagreb, Republic of Croatia.
authors.forename: P
authors.initials: P
authors.lastname: Sikiric
authors.forename: J
authors.initials: J
authors.lastname: Separovic
authors.forename: T
authors.initials: T
authors.lastname: Anic
authors.forename: G
authors.initials: G
authors.lastname: Buljat
authors.forename: D
authors.initials: D
authors.lastname: Mikus
authors.forename: S
authors.initials: S
authors.lastname: Seiwerth
authors.forename: Z
authors.initials: Z
authors.lastname: Grabarevic
authors.forename: D
authors.initials: D
authors.lastname: Stancic-Rokotov
authors.forename: B
authors.initials: B
authors.lastname: Pigac
authors.forename: M
authors.initials: M
authors.lastname: Hanzevacki
authors.forename: A
authors.initials: A
authors.lastname: Marovic
authors.forename: R
authors.initials: R
authors.lastname: Rucman
authors.forename: M
authors.initials: M
authors.lastname: Petek
authors.forename: I
authors.initials: I
authors.lastname: Zoricic
authors.forename: T
authors.initials: T
authors.lastname: Ziger
authors.forename: G
authors.initials: G
authors.lastname: Aralica
authors.forename: P
authors.initials: P
authors.lastname: Konjevoda
authors.forename: I
authors.initials: I
authors.lastname: Prkacin
authors.forename: M
authors.initials: M
authors.lastname: Gjurasin
authors.forename: P
authors.initials: P
authors.lastname: Miklic
authors.forename: B
authors.initials: B
authors.lastname: Artukovic
authors.forename: M
authors.initials: M
authors.lastname: Tisljar
authors.forename: M
authors.initials: M
authors.lastname: Bratulic
authors.forename: S
authors.initials: S
authors.lastname: Mise
authors.forename: I
authors.initials: I
authors.lastname: Rotkvic
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D062109:Dermatologic Surgical Procedures; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006097:Granulation Tissue / Q000187:drug effects* / Q000473:pathology; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009853:Omeprazole / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D011161:Porifera; D019736:Prostheses and Implants; D011506:Proteins / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013392:Sucralfate / Q000494:pharmacology*
chemical_list: D000897:Anti-Ulcer Agents; D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D010446:Peptide Fragments; D011506:Proteins; D013392:Sucralfate; C083833:BPC 157; D009853:Omeprazole